MovDisordV3, Main, Exploration, bibRecord, 003F38

Short‐term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing‐off phenomenon

Identifieur interne : 003F38 ( Main/Exploration ); précédent : 003F37; suivant : 003F39

Short‐term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing‐off phenomenon

Auteurs : Tomoyuki Uchiyama [Japon] ; Ryuji Sakakibara [Japon] ; Takamichi Hattori [Japon] ; Tomonori Yamanishi [Japon]

Source :

Movement Disorders [ 0885-3185 ] ; 2003-05.

RBID : ISTEX:C8E0CE8914A9D424EC7CF57953D4CE3A71325373

Descripteurs français

Pascal (Inist)
- Antiparkinsonien, Chimiothérapie, Court terme, Dose unique, Effet off, Homme, Lévodopa, Parkinson maladie, Traitement, Trouble miction.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Chemotherapy, Female, Human, Humans, Levodopa, Levodopa (pharmacology), Levodopa (therapeutic use), Male, Middle Aged, Muscle, Smooth (drug effects), Off effect, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Severity of Illness Index, Short term, Single dose, Time Factors, Treatment, Urethra (drug effects), Urethra (physiopathology), Urinary Bladder (drug effects), Urinary Incontinence (diagnosis), Urinary Incontinence (epidemiology), Urinary Incontinence (etiology), Urination Disorders (diagnosis), Urination Disorders (etiology), Urodynamics (drug effects), Voiding dysfunction, micturition disturbance, urodynamic study.
MESH :
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- complications : Parkinson Disease.
- diagnosis : Urinary Incontinence, Urination Disorders.
- drug effects : Muscle, Smooth, Urethra, Urinary Bladder, Urodynamics.
- drug therapy : Parkinson Disease.
- epidemiology : Urinary Incontinence.
- etiology : Urinary Incontinence, Urination Disorders.
- physiopathology : Urethra.
- Female, Humans, Male, Middle Aged, Severity of Illness Index, Time Factors.

Abstract

We investigated the short‐term effects of a single dose of levodopa (L‐dopa) on micturition function in PD patients with wearing‐off phenomenon. Eighteen PD patients who had median Hoehn and Yahr scores of 5 during the off phase and 3 during the on phase were recruited. We carried out urodynamic studies before and about 1 hour after the patients had taken 100 mg of L‐dopa with dopa‐decarboxylase inhibitor (DCI). After taking the L‐dopa/DCI, urinary urgency and urge incontinence aggravated, whereas voiding difficulty was alleviated in all 12 patients. When compared to the baseline assessment, urodynamic study results after taking 100 mg of L‐dopa/DCI showed aggravated detrusor hyperreflexia; decreased maximum bladder capacity (P = 0.006); an increased maximum Watts Factor value (P = 0.001), reflecting the detrusor power on voiding; an increased Abrams‐Griffiths number (P = 0.042), reflecting urethral obstruction on voiding; decreased residual urine volume (P = 0.025); and increased static urethral closure pressure (P = 0.012). One hundred milligrams of L‐dopa/DCI worsened detrusor hyperreflexia, producing worsened urinary urgency and urge incontinence during the storage (bladder‐filling) phase. It also increased detrusor contractility much more than it did urethral obstruction in the voiding phase, producing overall lessening of voiding difficulty and improving voiding efficiency in our PD patients with the wearing‐off phenomenon. © 2003 Movement Disorder Society

Url:

https://api.istex.fr/document/C8E0CE8914A9D424EC7CF57953D4CE3A71325373/fulltext/pdf

DOI: 10.1002/mds.10403

Affiliations:

Japon

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Short‐term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing‐off phenomenon</title>
<author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name>
</author>
<author><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name>
</author>
<author><name sortKey="Hattori, Takamichi" sort="Hattori, Takamichi" uniqKey="Hattori T" first="Takamichi" last="Hattori">Takamichi Hattori</name>
</author>
<author><name sortKey="Yamanishi, Tomonori" sort="Yamanishi, Tomonori" uniqKey="Yamanishi T" first="Tomonori" last="Yamanishi">Tomonori Yamanishi</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:C8E0CE8914A9D424EC7CF57953D4CE3A71325373</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1002/mds.10403</idno>
<idno type="url">https://api.istex.fr/document/C8E0CE8914A9D424EC7CF57953D4CE3A71325373/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000431</idno>
<idno type="wicri:Area/Istex/Curation">000431</idno>
<idno type="wicri:Area/Istex/Checkpoint">002867</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Uchiyama T:short:term:effect</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12722172</idno>
<idno type="wicri:Area/PubMed/Corpus">003788</idno>
<idno type="wicri:Area/PubMed/Curation">003788</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003635</idno>
<idno type="wicri:Area/Ncbi/Merge">000A63</idno>
<idno type="wicri:Area/Ncbi/Curation">000A63</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000A63</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Uchiyama T:short:term:effect</idno>
<idno type="wicri:Area/Main/Merge">005B60</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:03-0380996</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002453</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000868</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002318</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Uchiyama T:short:term:effect</idno>
<idno type="wicri:Area/Main/Merge">005E64</idno>
<idno type="wicri:Area/Main/Curation">003F38</idno>
<idno type="wicri:Area/Main/Exploration">003F38</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Short‐term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing‐off phenomenon</title>
<author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Neurology, Graduate School of Medicine, Chiba University, Chiba</wicri:regionArea>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Neurology, Graduate School of Medicine, Chiba University, Chiba</wicri:regionArea>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hattori, Takamichi" sort="Hattori, Takamichi" uniqKey="Hattori T" first="Takamichi" last="Hattori">Takamichi Hattori</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Neurology, Graduate School of Medicine, Chiba University, Chiba</wicri:regionArea>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yamanishi, Tomonori" sort="Yamanishi, Tomonori" uniqKey="Yamanishi T" first="Tomonori" last="Yamanishi">Tomonori Yamanishi</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Urology, Dokkyo University School of Medicine, Tochigi</wicri:regionArea>
<wicri:noRegion>Tochigi</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2003-05">2003-05</date>
<biblScope unit="vol">18</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="573">573</biblScope>
<biblScope unit="page" to="578">578</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">C8E0CE8914A9D424EC7CF57953D4CE3A71325373</idno>
<idno type="DOI">10.1002/mds.10403</idno>
<idno type="ArticleID">MDS10403</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (pharmacology)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (pharmacology)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Muscle, Smooth (drug effects)</term>
<term>Off effect</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Severity of Illness Index</term>
<term>Short term</term>
<term>Single dose</term>
<term>Time Factors</term>
<term>Treatment</term>
<term>Urethra (drug effects)</term>
<term>Urethra (physiopathology)</term>
<term>Urinary Bladder (drug effects)</term>
<term>Urinary Incontinence (diagnosis)</term>
<term>Urinary Incontinence (epidemiology)</term>
<term>Urinary Incontinence (etiology)</term>
<term>Urination Disorders (diagnosis)</term>
<term>Urination Disorders (etiology)</term>
<term>Urodynamics (drug effects)</term>
<term>Voiding dysfunction</term>
<term>micturition disturbance</term>
<term>urodynamic study</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Urinary Incontinence</term>
<term>Urination Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Muscle, Smooth</term>
<term>Urethra</term>
<term>Urinary Bladder</term>
<term>Urodynamics</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Urinary Incontinence</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Urinary Incontinence</term>
<term>Urination Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Urethra</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Court terme</term>
<term>Dose unique</term>
<term>Effet off</term>
<term>Homme</term>
<term>Lévodopa</term>
<term>Parkinson maladie</term>
<term>Traitement</term>
<term>Trouble miction</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We investigated the short‐term effects of a single dose of levodopa (L‐dopa) on micturition function in PD patients with wearing‐off phenomenon. Eighteen PD patients who had median Hoehn and Yahr scores of 5 during the off phase and 3 during the on phase were recruited. We carried out urodynamic studies before and about 1 hour after the patients had taken 100 mg of L‐dopa with dopa‐decarboxylase inhibitor (DCI). After taking the L‐dopa/DCI, urinary urgency and urge incontinence aggravated, whereas voiding difficulty was alleviated in all 12 patients. When compared to the baseline assessment, urodynamic study results after taking 100 mg of L‐dopa/DCI showed aggravated detrusor hyperreflexia; decreased maximum bladder capacity (P = 0.006); an increased maximum Watts Factor value (P = 0.001), reflecting the detrusor power on voiding; an increased Abrams‐Griffiths number (P = 0.042), reflecting urethral obstruction on voiding; decreased residual urine volume (P = 0.025); and increased static urethral closure pressure (P = 0.012). One hundred milligrams of L‐dopa/DCI worsened detrusor hyperreflexia, producing worsened urinary urgency and urge incontinence during the storage (bladder‐filling) phase. It also increased detrusor contractility much more than it did urethral obstruction in the voiding phase, producing overall lessening of voiding difficulty and improving voiding efficiency in our PD patients with the wearing‐off phenomenon. © 2003 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Japon</li>
</country>
</list>
<tree><country name="Japon"><noRegion><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name>
</noRegion>
<name sortKey="Hattori, Takamichi" sort="Hattori, Takamichi" uniqKey="Hattori T" first="Takamichi" last="Hattori">Takamichi Hattori</name>
<name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name>
<name sortKey="Yamanishi, Tomonori" sort="Yamanishi, Tomonori" uniqKey="Yamanishi T" first="Tomonori" last="Yamanishi">Tomonori Yamanishi</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003F38 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003F38 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:C8E0CE8914A9D424EC7CF57953D4CE3A71325373
   |texte=   Short‐term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing‐off phenomenon
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Short‐term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing‐off phenomenon

Short‐term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing‐off phenomenon

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.